Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dalteparin + sunitinib
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Subcutaneous, Oral
01
Overview
Dalteparin + sunitinib is a combination therapy investigated for the treatment of metastatic renal cell carcinoma (mRCC). Dalteparin is a low molecular weight heparin (LMWH) that acts as an anticoagulant by binding to antithrombin III and inhibiting Factor Xa. Sunitinib is an oral, multi-targeted tyrosine kinase inhibitor (TKI) that targets several receptor tyrosine kinases, including vascular endothelial growth factor receptors (VEGFRs) and platelet-derived growth factor receptors (PDGFRs). The combination was studied by the Roswell Park Cancer Institute based on the hypothesis that inhibiting both angiogenesis and the coagulation cascade—both of which are often upregulated in clear cell renal cell carcinoma—could provide synergistic anti-tumor effects and prevent thromboembolic complications common in cancer patients.
- Brand names
- Fragmin + Sutent
- Other names
- dalteparin sodium + sunitinib malateDalteparin and Sunitinib in Metastatic Renal Cell Carcinoma
02
Targets
ATIII (Antithrombin III)CSF1R (Macrophage colony-stimulating factor receptor)F2 (Thrombin)FLT3 (Fms related receptor tyrosine kinase 3)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDGFRA (Platelet-derived growth factor receptor alpha)PDGFRB (Platelet-derived growth factor receptor beta)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)F10 (Factor Xa)
Beyond the preview
Go deeper on dalteparin + sunitinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dalteparin + sunitinib.